Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes.

Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats. J Renal Inj Prev (2013) 1.57

Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol (2014) 1.00

Metformin: Current knowledge. J Res Med Sci (2014) 0.82

PGC-1 mediates the regulation of metformin in muscle irisin expression and function. Am J Transl Res (2015) 0.81

Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. PLoS One (2014) 0.79

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol (2016) 0.79

Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma. Curr Mol Med (2016) 0.78

Hyperglycemia in the intensive care unit: is insulin the only option? Crit Care (2013) 0.76

Re metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab (2013) 0.75

Drug-Induced Metabolic Acidosis. F1000Res (2015) 0.75

Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf (2016) 0.75

Lactate Levels with Chronic Metformin Use: A Narrative Review. Clin Drug Investig (2017) 0.75

Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore) (2017) 0.75

Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J Clin Endocrinol Metab (1994) 0.95

Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives. Diabetes Metab (2009) 0.91

Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr (2000) 0.82

How to measure insulin action in vivo. Diabetes Metab Rev (1994) 0.81

[Etiopathogenesis and pathophysiology of type 2 diabetes]. Rev Med Liege (2005) 0.80

Inflammatory markers and cardiometabolic diseases. Acta Clin Belg (2015) 0.80

Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies. Int J Obes Relat Metab Disord (1995) 0.79

Estimation of GFR by different creatinine- and cystatin-C-based equations in anorexia nervosa. Clin Nephrol (2009) 0.79

Non oxidative fructose disposal is not inhibited by lipids in humans. Diabetes Metab (1999) 0.79

[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents]. Rev Med Liege (2007) 0.78

[Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?]. Rev Med Suisse (2011) 0.78

Assessment of glucose metabolism in humans with the simultaneous use of indirect calorimetry and tracer techniques. Clin Physiol (1995) 0.77

[PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases]. Rev Med Liege (2005) 0.77

Autoregulation of endogenous glucose production in man. Biochem Soc Trans (1997) 0.76

[Metabolically obese normal-weight individuals and metabolically healthy, but obese, subjects]. Rev Med Suisse (2009) 0.75

[Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes]. Rev Med Suisse (2007) 0.75

[Glucotoxicity and lipotoxicity, two implicated accomplices in the vicious circle of type 2 diabetes]. Rev Med Liege (1999) 0.75

[Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials]. Rev Med Liege (2008) 0.75

[How should insulin sensitivity be evaluated in practice?]. Diabete Metab (1995) 0.75

[Metabolic surgery: an evolution (or revolution) of bariatric surgery?]. Rev Med Liege (2011) 0.75

[Type 2 diabetes: journey in the heart of a complex disease]. Rev Med Liege (2012) 0.75

[Blood glucose control and prevention of microangiopathy and macroangiopathy in type 2 diabetes]. Rev Med Liege (2003) 0.75

[How I explore ... the different forms of sugar diabetes: clinical and biological differental diagnosis]. Rev Med Liege (2001) 0.75

[Clinical case of the month. Apropos of a case of ectopic ACTH secretion]. Rev Med Liege (1995) 0.75

[What about the controversy regarding rosiglitazone]. Rev Med Liege (2007) 0.75

Energy and Nutrient Content of Food Served and Consumed by Nursing Home Residents. J Nutr Health Aging (2017) 0.75

[Pancreas transplantation in the management of diabetes]. Rev Med Liege (2005) 0.75

[Insulin detemir (Levemir)]. Rev Med Liege (2005) 0.75

[Energy expenditure in man]. Rev Med Liege (1997) 0.75

[Physiopathology of post-prandial hyperglycemia]. Journ Annu Diabetol Hotel Dieu (2006) 0.75

[Perspectives on atypical routes of insulin administration. Oral, rectal, and nasal routes]. Ann Endocrinol (Paris) (1988) 0.75

[Type II diabetes: diagnostic approaches, glycemia objectives and therapeutic strategies]. Rev Med Liege (1999) 0.75

[Clinical vignette. Which combination of oral glucose-lowering agents to use after failure of metformin monotherapy in type 2 diabetes?]. Rev Med Liege (2011) 0.75

[NLRP3 inflammasome and visceral adipose tissue]. Rev Med Liege (2014) 0.75

[The treatment of diabetic ketoacidosis in 1989]. Rev Med Liege (1989) 0.75

[Fitness versus fatness: respective cardiometabolic impacts at different age ranges]. Rev Med Liege (2010) 0.75

[ Change of insulin U40 to insulin U100: comparison of blood insulin and blood sugar in the diabetic patient]. Rev Med Liege (1991) 0.75

[How should insulin secretion be evaluated in practice?]. Diabete Metab (1995) 0.75

[How I investigate... a patient newly diagnosed with/or at risk of diabetes type 1]. Rev Med Liege (1997) 0.75

[Beta cells in Type II diabetes: culprit or victim?]. Journ Annu Diabetol Hotel Dieu (1991) 0.75

[Insulin sensitizers]. Rev Med Liege (2005) 0.75

[United Kingdom Prospective Diabetes Study (UKPDS): 10 years later]. Rev Med Liege (2008) 0.75

Effects of glucagon in the control of endogenous glucose production in man. Nutrition (1999) 0.75

[Postprandial hyperglycemia. II. Pharmacological approaches]. Rev Med Liege (2002) 0.75

[Adiponectin: a new adipocytokine]. Rev Med Liege (2003) 0.75

[Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study]. Rev Med Liege (2009) 0.75

Acute functional iron deficiency in obese subjects during a very-low-energy all-protein diet. Am J Clin Nutr (1997) 0.75

[Influence of body weight on the natural history of and the therapeutic approaches to type 1 diabetes]. Rev Med Liege (2012) 0.75

[Vildagliptin (Galvus) and fixed combination vildagliptine-metformin (Eucreas) in the treatment of type 2 diabetes]. Rev Med Liege (2009) 0.75

[Recent advances in the management of obesity]. Rev Med Liege (2007) 0.75

[Prevention of hypoglycemia in patients with type 1 diabetes]. Rev Med Liege (2003) 0.75

[Nutrition in the elderly]. Rev Med Liege (2014) 0.75

[Ultimate treatment of type 2 diabetes: intensive insulin therapy or bariatric surgery?]. Journ Annu Diabetol Hotel Dieu (1998) 0.75

[Hereditary hemochromatosis and diabetes mellitus: diagnostic approach and clinical evolution]. Rev Med Liege (2005) 0.75

[Thiazolidinediones]. Journ Annu Diabetol Hotel Dieu (1999) 0.75

[Type 1 diabetes and celiac disease]. Rev Med Liege (2006) 0.75

[Brain, a gluco-dependent organ: toxic effects of hypoglycaemia and hyperglycaemia]. Rev Med Liege (2008) 0.75

[Hematochromatosis and diabetes]. Rev Med Liege (2004) 0.75

[How to explore insulin sensitivity in man?]. Ann Endocrinol (Paris) (1995) 0.75

[TECOS: confirmation of the cardiovascular safety of sitaliptin]. Rev Med Liege (2015) 0.75

[Postprandial hyperglycemia. I. Physiopathology, clinical consequences and dietary management]. Rev Med Liege (2002) 0.75

[Management of an obese person with metabolic syndrome]. Rev Med Liege (2009) 0.75

[FROM EVIDENCE-BASED MEDICINE TO PERSONALIZED MEDICINE: THE EXEMPLE OF TYPE 2 DIABETES]. Rev Med Liege (2015) 0.75

[2015 updated position statement of the management of hyperglycaemia in type 2 diabetes]. Rev Med Suisse (2015) 0.75

[Use of metformin in diabetic patients with cardiac disease: benefit-risk balance]. Rev Med Suisse (2013) 0.75

[Clinical case of the month. Prolonged spontaneous remission of a typical type 1 diabetes]. Rev Med Liege (1995) 0.75

[Role of the liver in carbohydrate homeostasis: a re-reading of the works of Claude Bernard]. Journ Annu Diabetol Hotel Dieu (1996) 0.75

[Clinical evaluation of an obese person]. Rev Med Liege (2013) 0.75

[Diabetes mellitus in the elderly: from the epidemiological challenge to a personalized approach]. Rev Med Liege (2014) 0.75

[Beneficial effects of physical activity on cardiovascular risk factors]. Rev Med Liege (2001) 0.75

[How I explore ... the risk of a patient developing type 2 diabetes]. Rev Med Liege (2002) 0.75

[How I investigate the new criteria for the diagnosis of diabetes mellitus]. Rev Med Liege (1997) 0.75

[Type 2 insulin-dependent diabetes: patient characteristics and effects of insulin therapy]. Rev Med Liege (1994) 0.75

Measurement of insulin sensitivity by the minimal model method using a simplified intravenous glucose tolerance test: validity and reproducibility. Diabete Metab (1995) 0.75

[Metabolic surgery: an increasing place in the management of diabetes]. Rev Med Suisse (2012) 0.75

[Hyperlipemias and hypolipemic agents]. J Pharm Belg (1993) 0.75

[Therapeutic approaches to improve blood glucose control in a patient with type 2 diabetes on a metformin-sulfonylurea combination]. Rev Med Liege (2011) 0.75